RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
$ in Thousands

1 Months Ended

9 Months Ended

Dec. 15, 2021

Sep. 08, 2021

Dec. 31, 2021

Dec. 31, 2022

IfrsStatementLineItems [Line Items]

Portage ordinary shares

1,070,000

Annual feesDescription

Additionally, the chairperson of each of the Audit Committee, Compensation Committee and Nomination Committee will be entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears. Members of those committees will be entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears.

Compensation committee

$ 600

Original annual targets percentage

73.50%

Chief Executive Officers [Member]

IfrsStatementLineItems [Line Items]

Base Salary

$ 618,000

I O X [Member]

IfrsStatementLineItems [Line Items]

Issuance of unsecured notes, description

the Company, through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price of £162. Simultaneously, the Company entered into an agreement with OSI, the holder of $0.15 million notes plus accrued interest under which OSI exchanged the notes plus accrued interest for 820 shares of iOx. The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated November 29, 2016, following the general tenets of IAS 39, “Financial Instruments: Recognition and Measurement,” and IFRIC 19, “Extinguishing Financial Liabilities with Equity Instruments,” and recorded the exchange at historical cost. Additionally, no profit or loss was recorded in connection with the exchange. As a result of these transactions, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to 78.32%.